Overview
Bronchogen is described as a Khavinson bioregulatory peptide targeting bronchial and lung tissue, with molecular mass 446.45 g/mol and formula C18H30N4O9. It belongs to a family of very short peptides developed in Russian bioregulation research, where organ-associated peptides are proposed to influence gene expression, protein synthesis, and tissue function in age- or disease-altered systems.
The proposed mechanism is not a classic receptor agonist model like insulin or GLP-1. Khavinson literature describes short peptides interacting with DNA, chromatin, or gene-regulatory regions in a sequence-specific way. For Bronchogen, the claimed target is respiratory epithelium and bronchial mucosa, but independent replication and modern clinical trials are limited.
Bronchogen is not FDA-approved for COPD, asthma, bronchitis, lung repair, or immune support. Users should be cautious with marketing claims that turn thin mechanistic literature into treatment promises. Respiratory symptoms can signal serious disease, and peptide bioregulators should not delay inhalers, antibiotics, imaging, pulmonary testing, or smoking-cessation care when needed.
This guide explains the bioregulator theory, what can and cannot be inferred from the short-peptide literature, practical safety concerns, and how to evaluate Bronchogen without overstating the evidence.
Quick facts
- Mechanism
- Short peptide bioregulator proposed to influence respiratory tissue gene expression
- Primary use
- Respiratory Bioregulation Research
- Evidence
- limited
- FDA
- Not approved
- Route
- Oral or injectable research/bioregulator protocols
- Typical results
- Exploratory respiratory-tissue signaling claims with limited independent validation
Chemical information
Bronchogen is listed as a short peptide bioregulator with formula C18H30N4O9 and molecular mass 446.45 g/mol. The marketed identity is usually tied to Khavinson respiratory peptide concepts rather than a Western approved-drug monograph.
How Bronchogen works
Bronchogen is proposed to act through short-peptide regulation of gene expression in respiratory tissue. The general Khavinson model suggests that small peptides can enter cells, interact with DNA or chromatin, and modify protein synthesis patterns. This remains a specialized and incompletely validated framework, so claims should be described as exploratory.
For bronchial tissue, proposed endpoints include epithelial renewal, mucosal barrier function, inflammation tone, and markers of cellular proliferation or apoptosis. Those are plausible research domains because airway epithelium constantly responds to smoke, infection, allergens, and pollutants. However, Bronchogen-specific evidence is not comparable to FDA-reviewed respiratory drugs.
The broader short-peptide literature includes molecular modeling and experimental work on oligopeptide-DNA interactions. These studies support a mechanistic hypothesis but do not establish that every marketed bioregulator reaches the right tissue, concentration, or clinical endpoint after oral or injectable use. Sequence identity and product quality also vary across suppliers.
The practical interpretation is conservative: Bronchogen may be useful as a research subject in respiratory cell models, but it should not be presented as a proven therapy for obstructive lung disease, infection, fibrosis, or post-viral recovery.
- Bioregulator model: Proposed to influence tissue-specific gene-expression patterns
- Respiratory focus: Marketed toward bronchial and lung epithelial systems
- Barrier support hypothesis: Studied conceptually around mucosal renewal and repair
- Inflammation context: May intersect with airway inflammatory signaling in models
- Evidence gap: Limited independent human trial validation
- Product variability: Sequence, purity, and formulation should be verified
Pharmacokinetics
No reliable human pharmacokinetic profile for Bronchogen was found. Oral absorption, tissue distribution, half-life, and active intracellular concentrations should be considered unknown.
| Parameter | Value | Significance |
|---|---|---|
| Human PK | Not established | No validated half-life or exposure data |
| Route | Oral or injectable in market protocols | Clinical equivalence between routes is unproven |
| Bioavailability | Unknown | Short peptides may be degraded or transported variably |
| Target tissue | Proposed bronchial/lung tissue | Tissue targeting has not been independently confirmed |
| Metabolism | Peptidase degradation expected | Likely broken down into amino acids or small fragments |
| Onset | Not established | Symptom timelines in marketing are not validated endpoints |
Dosing & administration
There is no FDA-approved Bronchogen dose. Bioregulator protocols often use short cycles and either oral capsules or injections, but these schedules come from tradition, vendor material, or regional practice rather than modern dose-finding trials.
A responsible research protocol would define the exact peptide sequence, route, purity, respiratory model, biomarkers, pulmonary function measures, and adverse-event monitoring. Without these controls, perceived improvements are hard to separate from placebo effects or natural symptom fluctuation.
Anyone with wheezing, shortness of breath, chest pain, fever, low oxygen saturation, or chronic cough should prioritize medical evaluation. Bronchogen should not replace inhaled bronchodilators, corticosteroids, antibiotics, pulmonary rehabilitation, or smoking cessation.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Bronchogen's main safety issue is not a well-defined toxicity signal but the absence of robust human data. Respiratory disease can become urgent quickly, so investigational peptides should never delay evidence-based care.
Common
- • Injection site irritation if injected
- • Mild gastrointestinal upset if oral
- • Headache or fatigue reported anecdotally
- • Allergic-type reaction to product impurities
- • No measurable respiratory change
- • Confusion with standard respiratory therapy
Serious / potential risks
- • Delayed treatment of asthma, COPD, pneumonia, or pulmonary embolism
- • Unknown immune effects in autoimmune or inflammatory lung disease
- • Contamination from unregulated injectable material
- • Hypersensitivity reaction
- • Unknown long-term safety in humans
Drug interactions
Formal interaction studies are not available; interaction concerns are based on respiratory disease context and unvalidated immune effects.
| Medication | Interaction | Recommendation |
|---|---|---|
| Inhaled corticosteroids | No known direct interaction, but may confound symptom tracking | Do not stop prescribed inhalers |
| Bronchodilators | No established pharmacologic overlap | Continue physician-directed therapy |
| Immunosuppressants | Unknown immune-modulating implications | Avoid unsupervised use |
| Antibiotics | Peptide use may delay infection treatment if misused | Treat bacterial infection appropriately |
| Other bioregulators | Stacking effects are unstudied | Avoid multi-peptide attribution errors |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Bioregulator capsules | $40-$120 per cycle | Often sold in short 10-30 day courses |
| Research peptide vials | $50-$200+ | Verify sequence and purity if used in research |
| Clinical wellness programs | $200-$600+ per program | Usually bundled with other interventions |
The bottom line
Bronchogen is best viewed as a respiratory bioregulator research compound with limited, hard-to-verify clinical support. It may be interesting for airway epithelial models, but it is not a substitute for proven respiratory diagnosis or treatment.
Best for
- • Researchers studying short peptide bioregulation in airway models
- • Literature reviews of Khavinson respiratory peptides
- • Careful exploratory protocols with objective pulmonary endpoints
Not for
- • Acute asthma or COPD flare management
- • Pneumonia, chest pain, or low oxygen symptoms
- • Replacing prescribed inhalers
- • Users expecting FDA-reviewed respiratory therapy
Related compounds
Acetic Acid
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Amino Tadalafil
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
AOD-9604
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Astressin-B
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Frequently asked questions
References
- [1] Khavinson VK, Anisimov VN. Peptide regulation of aging: 35-year research experience. Bulletin of Experimental Biology and Medicine (2009). doi: 10.1007/s10517-009-0650-8 PMID: 19902107
- [2] Khavinson VK, Solovyov AY, Shataeva LK. Molecular mechanism of interaction between oligopeptides and double-stranded DNA. Bulletin of Experimental Biology and Medicine (2006). doi: 10.1007/s10517-006-0198-9 PMID: 17152370
- [3] Khavinson VK. Peptides, genome, aging. Advances in Gerontology (2014). PMID: 25306656
- [4] Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters (2003). PMID: 14523363
- [5] Khavinson VK, Solovev AY. Short peptides regulate gene expression. Biology Bulletin Reviews (2013).
- [6] Vanyushin BF, Khavinson VK. Short peptides as epigenetic regulators of gene expression. Russian Journal of Bioorganic Chemistry (2016).